At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Martin Reck, MD, PhD, from LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses an evaluation of overall health status in patients with advanced squamous non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 antibody, or docetaxel in CheckMate 017; and subgroup analyses and patient reported outcomes in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057.
Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancer
4th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now